HO-1 is a prototypic NRF2 target gene, and the aberrant hyperactivation of signaling mediated by NRF2/HO-1 axis contributes to tumor progression, aggressiveness, chemoresistance, and poor prognosis [30]. This evidence concerns the gene NFE2L2 and neoplasm.